Psoriasis frequently progresses to PsA, and it has been uncertain whether drugs targeting TNF can delay or prevent it. This retrospective analysis examined progression rates in patients with severe ...

Among patients with psoriasis who have active or recent cancer, biologic therapies show similar cancer progression or recurrence and serious infection rates compared with conventional systemic agents.

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

The TNF alpha inhibitors adalimumab and infliximab were associated with an increased risk for serious infection in patients with plaque psoriasis.

Tampa, FL - Psoriasis occurring in patients with chronic arthritic conditions treated with TNF inhibitors has been described as an adverse effect of these drugs?a paradoxical side effect, because TNF ...

Tumour necrosis factor alpha (TNF-α) inhibitors are licensed for use in autoimmune conditions such as psoriasis, and there have been reported cases of liver injury associated with infliximab and ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriasis treated with tumor necrosis factor inhibitors should adhere to a Mediterranean diet.

PsO is a systemic inflammatory disease that presents not only as scaly skin lesions, erythema, and itching but also affects ...

Until about 20 years ago, systemic treatment options for moderate/severe psoriasis were limited and nonspecific. To get an idea of how much the field has changed, clinical guidelines on psoriasis ...